
    
      This is a double-blind, placebo controlled study in subjects with moderate to severe acne.
      Subjects who satisfy the entry criteria will be randomized to SB204 4% QD or Vehicle Gel QD
      in a 1:1 ratio. Efficacy assessments will include Investigator Global Assessments (IGA) and
      inflammatory and non-inflammatory lesion counts. Subjects will return for post-Baseline
      evaluation at Weeks 2, 4, 8, and 12/Early Termination (ET).
    
  